<DOC>
	<DOCNO>NCT00141947</DOCNO>
	<brief_summary>In propose study , aim investigate effect Bexarotene ( Targretin ; LGD1069 ; 4- [ 1- { 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl } ethenyl ] benzoic acid ) severity psychopathology , cognitive impairment , quality life schizophrenia patient open label trial . The rationale behind add-on oral bexarotene ongoing antipsychotic treatment schizophrenia patient base retinoid dysregulation hypothesis ( Goodman , 1995 ) growth factor deficiency synaptic destabilization hypothesis ( Moises et al , 2002 ) schizophrenia . In clinical trial , novel regimen low dose bexarotene ( Targretin , 75 mg/day ) add 6 week standard treatment 15 schizophrenia patient stable antipsychotic treatment . Participants assess baseline 2 , 4 6 week treatment . A battery research instrument use assessment efficacy safety ( psychopathology , side effect ) . In addition , cholesterol triglyceride level , liver thyroid function test blood cell count monitor baseline therapy .</brief_summary>
	<brief_title>Bexarotene Treatment Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>age 1860 schizophrenia stable blood parameter normal baseline fast triglyceride ability sign inform consent lipid abnormality leukopenia neutropenia organic brain damage ( mental retardation ) alcohol drug abuse renal disease hepatic dysfunction history pancreatitis thyroid axis alteration suicide attempt past year cataract systemic treatment 15,000IU vitamin A daily patient know hypersensitivity bexarotene component product pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>bexarotene</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>psychopathology</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>quality life</keyword>
	<keyword>open lable trial</keyword>
</DOC>